Keyphrases
Retroperitoneal Surgery
100%
Residual Mass
100%
Non-seminomatous Germ Cell Tumor (NSGCT)
100%
Photodynamic Diagnosis
100%
Oncological Complications
100%
Non-inferiority Trial
100%
Tumor Resection
100%
Post-chemotherapy
100%
Resection
100%
Bladder Tumor
100%
Prospective Randomized Trial
100%
Laser Destruction
100%
Transurethral
100%
Oncological Outcomes
100%
Major Complications
100%
Intermediate Risk
100%
Tumor
66%
Open Surgery
66%
Recurrence Rate
66%
Laparoscopic Surgery
66%
Retroperitoneal Lymph Node Dissection (RPLND)
66%
Bilateral Surgery
66%
Robotic Surgery
66%
Photocoagulation
40%
Patient Management
33%
General Anesthesia
33%
Patient Selection
33%
Published Data
33%
Newcastle-Ottawa Scale
33%
Patient Demographics
33%
Embase
33%
Cochrane Database
33%
Retroperitoneum
33%
Long Follow-up
33%
Transurethral Resection
33%
Lymph Node Resection
33%
MEDLINE
33%
Robotics
33%
Surgical Technique
33%
Complication Risk
33%
Risk of Bias
33%
Clavien-Dindo Classification
33%
PubMed
33%
Confidence Interval
26%
Recurrence-free Survival
20%
Outpatient Department
20%
Transurethral Resection of Bladder Tumor (TURBT)
13%
Minor Complications
13%
Laser Technology
6%
Postoperative Complications
6%
Medicine and Dentistry
Non Seminomatous Germinoma
100%
Outpatient
100%
Bladder Tumor
100%
Systematic Review
100%
DNA Template
100%
Cancer Surgery
100%
Clinical Trial
100%
Retroperitoneal Lymph Node Dissection
50%
Recurrent Disease
50%
Laser Coagulation
50%
Surgery
50%
Transurethral Resection
43%
Neoplasm
39%
Open Surgery
33%
Robot-Assisted Surgery
33%
Recurrence Risk
33%
Laparoscopic Surgery
33%
General Anesthesia
31%
Recurrence Free Survival
18%
Surgical Technique
16%
Patient Population
16%
Retroperitoneum
16%
Patient Selection
16%
Health Care Cost
6%
Tumor Recurrence
6%
Laser Technology
6%
Health Care
6%
Postoperative Complication
6%
Patient Preference
6%
Outcome Assessment
6%
Noninferiority Trial
6%
Local Anesthesia
6%
Quality of Life
6%
Bladder
6%
Lower Urinary Tract Symptom
6%
